Randomized phase II trial of dabrafenib and trametinib with or without navitoclax in patients (pts) with BRAF-mutant (MT) metastatic melanoma (MM) (CTEP P9466).Zeynep Eroglu,Janice M. Mehnert,Anita Giobbie-Hurder,Kari Lynn Kendra,Gino Kim In,April K. S. Salama,Gary C. Doolittle, Jeffrey A. Sosman, Jennifer Brooke Valerin,Theresa Michelle Medina,Jose Lutzky,Stergios J. Moschos,Nikhil I. Khushalani,Joseph Markowitz,Naoko Takebe,Helen X. Chen, Laura W. Knight,Michael A. Davies,Ryan J. SullivanJOURNAL OF CLINICAL ONCOLOGY（2023）引用 0|浏览24暂无评分关键词melanoma,dabrafenib,navitoclax,braf-mutantAI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
